A Phase 1b Study to Assess the Safety, Tolerability, PK and PD of MG1113 in Hemophilia Patient
NCT05493631
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
15
Enrollment
INDUSTRY
Sponsor class
Conditions
Hemophilia
Interventions
BIOLOGICAL:
MG1113
Sponsor
GC Biopharma Corp